DSGN
Income statement / Annual
Last year (2024), Design Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Design Therapeutics, Inc.'s net income was -$49.59 M.
See Design Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$226.00 |
$834.00 |
Cost of Revenue |
$0.00
|
$537,000.00
|
$466,000.00
|
$129,000.00
|
$5,000.00
|
$1,654.00
|
Gross Profit |
$0.00
|
-$537,000.00
|
-$466,000.00
|
-$129,000.00
|
-$4,774.00
|
-$820.00
|
Gross Profit Ratio |
0
|
0
|
0
|
0
|
-21.12
|
-0.98
|
Research and Development Expenses |
$44.35 M
|
$57.06 M
|
$48.61 M
|
$24.78 M
|
$6.06 M
|
$1.65 M
|
General & Administrative Expenses |
$18.03 M
|
$21.13 M
|
$18.98 M
|
$11.05 M
|
$2.50 M
|
$1.09 M
|
Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General & Administrative Expenses |
$18.03 M
|
$21.13 M
|
$18.98 M
|
$11.05 M
|
$2.50 M
|
$1.09 M
|
Other Expenses |
$0.00
|
$0.00
|
$4.29 M
|
$298,000.00
|
-$226,000.00
|
-$834,000.00
|
Operating Expenses |
$62.38 M
|
$78.19 M
|
$67.59 M
|
$35.83 M
|
$8.33 M
|
$1.91 M
|
Cost And Expenses |
$0.00
|
$78.19 M
|
$67.59 M
|
$35.83 M
|
$8.33 M
|
$1.91 M
|
Interest Income |
$12.80 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Depreciation & Amortization |
$0.00
|
$537,000.00
|
$466,000.00
|
$129,000.00
|
$5,000.00
|
$1.91 M
|
EBITDA |
-$62.38 M |
-$66.33 M |
-$62.84 M |
-$35.70 M |
-$8.33 M |
-$139,000.00 |
EBITDA Ratio |
0
|
0
|
0
|
0
|
-36836.28
|
-2287.77
|
Operating Income Ratio |
0
|
0
|
0
|
0
|
-36858.41
|
-2287.77
|
Total Other Income/Expenses Net |
$12.80 M
|
$11.33 M
|
$4.29 M
|
$298,000.00
|
$50,000.00
|
-$139,000.00
|
Income Before Tax |
-$49.59 M
|
-$66.86 M
|
-$63.31 M
|
-$35.53 M
|
-$8.28 M
|
-$2.05 M
|
Income Before Tax Ratio |
0
|
0
|
0
|
0
|
-36637.17
|
-2454.44
|
Income Tax Expense |
$0.00
|
-$1.00
|
-$4.69 M
|
-$107,558.00
|
-$201,297.00
|
-$1,908.00
|
Net Income |
-$49.59 M
|
-$66.86 M
|
-$58.62 M
|
-$35.53 M
|
-$8.28 M
|
-$2.05 M
|
Net Income Ratio |
0
|
0
|
0
|
0
|
-36637.17
|
-2454.44
|
EPS |
-0.88 |
-1.19 |
-1.05 |
-0.77 |
-0.3 |
-0.0753 |
EPS Diluted |
-0.88 |
-1.19 |
-1.05 |
-0.77 |
-0.3 |
-0.0753 |
Weighted Average Shares Out |
$56.59 M
|
$55.98 M
|
$55.71 M
|
$45.94 M
|
$27.19 M
|
$27.19 M
|
Weighted Average Shares Out Diluted |
$56.59 M
|
$55.98 M
|
$55.71 M
|
$45.94 M
|
$27.19 M
|
$27.19 M
|
Link |
|
|
|
|
|
|